OBJECTIVE: The objective of this study was to compare the reduction in size of experimentally induced choroidal neovascularization (CNV) in rat eyes treated with bevacizumab, poly(ethylene-glycol) (PEG)-bevacizumab conjugate (b-PEG), and poly(lactic-co-glycolic acid) (PLGA)-encapsulated bevacizumab (b-PLGA). METHODS: Forty-eight eyes from 24 rats were divided into 4 groups of 12 eyes. In each group, 3 eyes were assigned to a treatment subgroup, each receiving a different injection-control, bevacizumab, b-PEG, and b-PLGA. In all eyes, laser photocoagulation was used to rupture Bruch's membrane. In group 1, laser was followed by injection, which was then followed by harvesting the rats to assess the CNV area. All 3 steps were separated by a 2-week interval. In groups 2, 3, and 4, injection preceded laser photocoagulation by a variable interval and all rats were harvested 2 weeks postlaser treatment. In group 2, laser and injection were separated by 2 weeks. In group 3, laser followed injection by 4 weeks. In group 4, laser followed injection by 6 weeks. The CNV area was measured for each subgroup and compared against its control. Pairwise comparisons were conducted to assess for statistically significant differences between subgroups. RESULTS: All subgroups in groups 1, 2, and 4 showed statistically significant reduction of CNV area (P<0.05). In group 3, the b-PEG and b-PLGA subgroups showed a 9.0% (P=0.384) and 20.3% (P=0.077) reduction in CNV area versus control, whereas there was no reduction in CNV area in the bevacizumab subgroup. However, this was not found to be statistically significant. In group 4, b-PEG was more effective than bevacizumab and b-PLGA. CONCLUSION: The reduction in CNV area in all treatment subgroups, with the exception of those in group 3, suggests successful creation of the 2 bevacizumab formulations while retaining its active antiangiogenic properties. Further studies varying in dosages and timing of injection and laser are needed to evaluate the formulations' long-acting efficacy.
OBJECTIVE: The objective of this study was to compare the reduction in size of experimentally induced choroidal neovascularization (CNV) in rat eyes treated with bevacizumab, poly(ethylene-glycol) (PEG)-bevacizumab conjugate (b-PEG), and poly(lactic-co-glycolic acid) (PLGA)-encapsulated bevacizumab (b-PLGA). METHODS: Forty-eight eyes from 24 rats were divided into 4 groups of 12 eyes. In each group, 3 eyes were assigned to a treatment subgroup, each receiving a different injection-control, bevacizumab, b-PEG, and b-PLGA. In all eyes, laser photocoagulation was used to rupture Bruch's membrane. In group 1, laser was followed by injection, which was then followed by harvesting the rats to assess the CNV area. All 3 steps were separated by a 2-week interval. In groups 2, 3, and 4, injection preceded laser photocoagulation by a variable interval and all rats were harvested 2 weeks postlaser treatment. In group 2, laser and injection were separated by 2 weeks. In group 3, laser followed injection by 4 weeks. In group 4, laser followed injection by 6 weeks. The CNV area was measured for each subgroup and compared against its control. Pairwise comparisons were conducted to assess for statistically significant differences between subgroups. RESULTS: All subgroups in groups 1, 2, and 4 showed statistically significant reduction of CNV area (P<0.05). In group 3, the b-PEG and b-PLGA subgroups showed a 9.0% (P=0.384) and 20.3% (P=0.077) reduction in CNV area versus control, whereas there was no reduction in CNV area in the bevacizumab subgroup. However, this was not found to be statistically significant. In group 4, b-PEG was more effective than bevacizumab and b-PLGA. CONCLUSION: The reduction in CNV area in all treatment subgroups, with the exception of those in group 3, suggests successful creation of the 2 bevacizumab formulations while retaining its active antiangiogenic properties. Further studies varying in dosages and timing of injection and laser are needed to evaluate the formulations' long-acting efficacy.
Authors: Frank G Holz; Jean-François Korobelnik; Paolo Lanzetta; Paul Mitchell; Ursula Schmidt-Erfurth; Sebastian Wolf; Sabri Markabi; Heinz Schmidli; Andreas Weichselberger Journal: Invest Ophthalmol Vis Sci Date: 2009-08-06 Impact factor: 4.799
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams Journal: Am J Ophthalmol Date: 2008-02 Impact factor: 5.258
Authors: Ron B Shmueli; Masayuki Ohnaka; Akiko Miki; Niranjan B Pandey; Raquel Lima e Silva; Jacob E Koskimaki; Jayoung Kim; Aleksander S Popel; Peter A Campochiaro; Jordan J Green Journal: Biomaterials Date: 2013-07-10 Impact factor: 12.479
Authors: Britta M Rauck; Thomas R Friberg; Carlos A Medina Mendez; Daewon Park; Veeral Shah; Richard A Bilonick; Yadong Wang Journal: Invest Ophthalmol Vis Sci Date: 2014-01-23 Impact factor: 4.799
Authors: Jeffrey J Tan; Charles L Cai; Eric M Shrier; Lois McNally; Douglas R Lazzaro; Jacob V Aranda; Kay D Beharry Journal: J Ophthalmol Date: 2017-07-09 Impact factor: 1.909
Authors: Iacovos P Michael; Peter D Westenskow; Sabiha Hacibekiroglu; Alissa Cohen Greenwald; Brian G Ballios; Toshihide Kurihara; Zhijie Li; Carmen M Warren; Puzheng Zhang; Edith Aguilar; Laura Donaldson; Valentina Marchetti; Takeshi Baba; Samer M Hussein; Hoon-Ki Sung; M Luisa Iruela-Arispe; James M Rini; Derek van der Kooy; Martin Friedlander; Andras Nagy Journal: EMBO Mol Med Date: 2014-05 Impact factor: 12.137
Authors: Yue Li; Ahmad M N Alhendi; Mei-Chun Yeh; Mina Elahy; Fernando S Santiago; Nandan P Deshpande; Ben Wu; Enoch Chan; Shafqat Inam; Leonel Prado-Lourenco; Jessica Marchand; Rohan D Joyce; Lorna E Wilkinson-White; Mark J Raftery; Meidong Zhu; Samuel J Adamson; François Barnat; Karen Viaud-Quentric; Jim Sockler; Joel P Mackay; Andrew Chang; Paul Mitchell; Sebastian M Marcuccio; Levon M Khachigian Journal: Sci Adv Date: 2020-07-29 Impact factor: 14.136